Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo

British Journal of Pharmacology

Volumn 162, Issue 2, 2011, Pages 480-490

  Finch, Dk ^a   Midha, A ^b   Buchanan, C ^a   Cochrane, D ^a   Craggs, R I ^b   Cruwys, S ^b   Grahames, C ^b   Kolbeck, R ^a   Lowe, D C ^a   Maltby, J ^b   Pattison, D V ^a   Vousden, K A ^a   Ward, A ^b   Sleeman, M A ^a   Mallinder, P R ^b  

^a MEDIMMUNE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

antibody; IL 15; inflammation; interleukin; lymphocyte; trans presentation

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DISC0280; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BIOTINYLATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PURIFICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BINDING SITES; CELL PROLIFERATION; CYTOKINES; HUMANS; INTERLEUKIN-15; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78650368274     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01061.x     Document Type: Article

References (38)

1. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, et al. (2005). Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 52: 2686-2692.
2. Bergamaschi C, Rosati M, Jalah R, Valentin A, Kulkarni V, Alicea C, et al. (2008). Intracellular interaction of interleukin-15 with its receptor alpha during production leads to a mutual stabilisation and increased bioactivity. J Biol Chem 283: 4189-4199.
3. Bernard J, Harb C, Mortier E, Quemener A, Meloen RH, Vermot-Desroches C, et al. (2004). Identification of an interleukin-15alpha receptor-binding site on human interleukin-15. J Biol Chem 279: 24313-24322.
4. Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, et al. (2008). The exon-3-encoded domain of IL-15Rα contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Rα. J Mol Biol 382: 1-12.
5. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J, (2006). Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311: 1924-1927.
6. Budagian V, Bulanova E, Orinska Z, Pohl T, Borden EC, Silverman R, et al. (2004). Reverse signaling through membrane-bound interleukin-15. J Biol Chem 279: 42192-42201.
7. Bulanova E, Budagian V, Duitman E, Orinska Z, Krause H, Ruckert R, et al. (2007). Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem 282: 13167-13179.
8. + T cell homeostasis. J Exp Med 200: 825-834.
9. Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR, (2008). Preassociation of IL-15 with IL-15Rα-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T Cells and its antitumor action. J Immunol 180: 2099-2106.
10. Eisenman J, Ahdieh M, Beers C, Brasel K, Kennedy MK, Le T, et al. (2002). Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 20: 121-129.
11. Fehniger TA, Caligiuri MA, (2001). Interleukin 15: biology and relevance to human disease. Blood 97: 14-32.
12. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, Kumaki S, et al. (1994). Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13: 2822-2830.
13. Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, et al. (1995). Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 14: 3654-3663.
14. Giron-Michel J, Giuliani M, Fogli M, Brouty-Boye D, Ferrini S, Baychelier F, et al. (2005). Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood 106: 2302-2310.
15. Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S, et al. (1987). Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 70: 1069-1072.
16. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. (2009). IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 206: 25-34.
17. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. (2000). Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191: 771-780.
18. Lodolce JP, Burkett PR, Koka RM, Boone DL, Ma A, (2002). Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev 13: 429-439.
19. Loza M, Zamai L, Azzoni L, Rosati E, Perussia B, (2002). Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 99: 1273-1281.
20. Ma A, Koka R, Burkett P, (2006). Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 24: 657-679.
21. McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY, (1997). Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 3: 189-195.
22. Meazza R, Basso S, Gaggero A, Detotero D, Trentin L, Pereno R, et al. (1998). Interleukin (IL)-15 induces survival and proliferation of the growth factor-dependent acute myeloid leukemia M-07e through the IL-2 receptor beta/gamma. Int J Cancer 78: 189-195.
23. Mori A, Suko M, Kaminuma O, Inoue S, Ohmura T, Nishizaki Y, et al. (1996). IL-15 promotes cytokine production of human T helper cells. J Immunol 156; 2400-2405.
24. Mortier E, Bernard J, Plet A, Jacques Y, (2004). Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 173: 1681-1688.
25. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, et al. (2006). Soluble interleukin-15 receptor alpha (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rbeta/gamma: hyperagonist IL-15- IL-15Rα fusion proteins. J Biol Chem 281: 1612-1619.
26. Mortier E, Woo T, Advincula R, Gozalo S, Ma A, (2008). IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med 205: 1213-1225.
27. Olsen SK, Ota N, Kishishita S, Kukimoto-Niino M, Murayama K, Uchiyama H, et al. (2007). Crystal structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentation. J Biol Chem 282: 37191-37204.
28. + T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol 169: 4928-4935.
29. Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, et al. (2006). Converting IL-15 to a superagonist by binding to soluble IL-15Rα. Proc Natl Acad Sci U S A 103: 9166-9171.
30. Ruchatz H, Leung BP, Wei XQ, McInnes IB, Liew FY, (1998). Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology. J Immunol 160: 5654-5660.
31. Ruckert R, Brandt K, Braun A, Hoymann HG, Herz U, Budagian V, et al. (2005). Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation in vivo. J Immunol 174: 5507-5515.
32. Sandau MM, Schluns KS, Lefrancois L, Jameson SC, (2004). Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R alpha by the same cells. J Immunol 173: 6537-6541.
33. Stoklasek TA, Schluns KS, Lefrancois L, (2006). Combined IL-15/IL-15Rα immunotherapy maximizes IL-15 activity in vivo. J Immunol 177: 6072-6080.
34. Thompson J, Pope T, Tung J-S, Chan C, Hollis G, Mark G, et al. (1996). Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J Mol Biol 256: 77-88.
35. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. (1996). Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14: 309-314.
36. Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, et al. (2003). Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 112: 1571-1580.
37. Waldmann TA, Tagaya Y, (1999). The multifaceted regulation of Interleukin-15 expresssion and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17: 19-49.
38. Wuttge DM, Wildt M, Geborek P, Wollheim FA, Scheja A, Akesson A, (2007). Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease. Arthritis Res Ther 9: R85.